Jan 25, 2013

Farmak JSC has introduced L’esfal hepatoprotector to the market

Farmak’s specialists have developed L’esfal hepatoprotective drug of broad use spectrum and introduced it to the market. A new product is released in form of solution for injections.

L’esfal contains essential phospholipids (1 ml solution contains phosphatidylcholine out of soybeans 50 mg), needed to recover the structure and functions of the liver cells. 

Kateryna Myrgorodska, Farmak’s Product Manager of OTC Drugs Marketing Department: L’esfal is prescribed for the treatment of acute and chronic hepatitis, cirrhosis, fat and alcoholic liver disease, toxicosis in pregnant women and dermatological diseases.

The drug not only protects the liver from different destructive effects but recovers its affected structure. It should be noted that L’esfal may be prescribed for the children aged 12 years and older and pregnant and breast-feeding women”.

Back to the News